Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
Lawrence BlondeTimothy S BaileyJason ChaoTerry A DexJuan Pablo FriasLuigi F MeneghiniMichelle RobertsVanita R ArodaPublished in: Advances in therapy (2019)
Sanofi US, Inc.